Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis

Completed · Phase 1/Phase 2

Conditions studied: Dermatitis, Atopic

In brief

The purpose of this study is to investigate the safety, tolerability, and systemic exposure of AN2728 Topical Ointment, 2%, in subjects with atopic dermatitis.

Key facts

Study ID

NCT01652885

Run by

Pfizer

People needed

23

Starts

2012-07-01

Expected to finish

2012-11-01

Last updated by the study team

2017-04-24

Who can join

Age: 12 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female 12 to 17 years of age, inclusive
• Clinical diagnosis of atopic dermatitis (according to the criteria of Hanifin and Rajka)
• AD in treatable areas (excludes the scalp and venous access areas) involving
• ≥10% and ≤35% of the total body surface area(BSA)
• Investigator's Static Global Assessment (ISGA) score of 2 or 3
• Normal or not clinically significant screening laboratory results
• Have adequate venous access to permit repeated PK sampling on Days 1 - 9 through uninfected skin that has not been treated with study drug; each untreated venous access area should provide a margin of at least 5 cm radius around the venipuncture site
• Willing and able to comply with study instructions and commit to attending all visits
• Females must use a highly effective method of birth control.
• Parent/guardian has the ability to understand, agree to and sign the study Informed Consent Form (ICF) prior to initiation of any protocol-related procedures; subject has the ability to give assent

You may not qualify if…

• Significant confounding conditions as assessed by study doctor
• Unstable or actively infected AD
• Active or potentially recurrent dermatologic condition other than atopic dermatitis that may confound evaluation
• History or evidence of allergies requiring acute or chronic treatment (except seasonal allergic rhinitis)
• Concurrent or recent use of certain topical or systemic medications or phototherapy without a sufficient washout period
• Treatment for any type of cancer (except squamous cell carcinoma, basal cell carcinoma, or carcinoma in situ of the skin, curatively treated with cryosurgery or surgical excision only) within the last 5 years
• Current pregnancy or lactation, or intent to become pregnant during the study
• Known sensitivity to any of the components of the study drug
• Participated in any other trial of an investigational drug or device within 30 days or participation in a research study concurrent with this study
• Participated in a previous AN2728 clinical study

Where it is running

• Anacor Investigational Site — Fremont, California, United States
• Anacor Investigational Site — San Diego, California, United States
• Anacor Investigational Site — Indianapolis, Indiana, United States
• Anacor Investigational Site — High Point, North Carolina, United States
• Anacor Investigational Site — Winston-Salem, North Carolina, United States
• Anacor Investigational Site — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.